Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.

Autor: Nevalainen OPO; Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.; Hatanpää Health Center, City of Tampere, Tampere, Finland.; Pirkanmaa Hospital District, Tampere, Finland., Horstia S; Faculty of Medicine, University of Helsinki, Helsinki, Finland., Laakkonen S; Faculty of Medicine, University of Helsinki, Helsinki, Finland., Rutanen J; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Mustonen JMJ; Occupational Health Helsinki, City of Helsinki, Helsinki, Finland., Kalliala IEJ; Department of Obstetrics and Gynaecology, Helsinki University and University Hospital Helsinki, Helsinki, Finland.; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK., Ansakorpi H; Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland., Kreivi HR; Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Kuutti P; Faculty of Medicine, University of Helsinki, Helsinki, Finland., Paajanen J; Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Parkkila S; Faculty of Medicine and Health Technology, Tampere University and Fimlab Ltd., Tampere University Hospital, Tampere, Finland., Paukkeri EL; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Perola M; Department of Public Health and Welfare, Population Health Unit, Public Health Research Team, Finnish Institute for Health and Welfare, Helsinki, Finland.; Clinical and Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Pourjamal N; Faculty of Medicine, University of Helsinki, Helsinki, Finland., Renner A; Department of Pulmonology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Rosberg T; Department of Pulmonology, Kanta-Häme Central Hospital, Hämeenlinna, Finland., Rutanen T; Suomen Covid -yhdistys ry, Helsinki, Finland., Savolainen J; Suomen Covid -yhdistys ry, Helsinki, Finland., Haukka JK; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Clinicum/Department of Public Health, University of Helsinki, Helsinki, Finland., Guyatt GH; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.; Department of Medicine, McMaster University, Hamilton, ON, Canada., Tikkinen KAO; Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. kari.tikkinen@helsinki.fi.; Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland. kari.tikkinen@helsinki.fi.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Oct 18; Vol. 13 (1), pp. 6152. Date of Electronic Publication: 2022 Oct 18.
DOI: 10.1038/s41467-022-33825-5
Abstrakt: We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: